Transthyretin has conformation-selective proteolytic activity against α-synuclein
Z. Sarkany, T. Giao, M. A. Liz, A. Planas, S. Macedo-Ribeiro, I. Cardoso, G. Arsequell, P. M. Martins
Abstract
Transthyretin (TTR) is a plasma protein known as a transporter of thyroxine and retinol but also can inhibit the formation of amyloid {beta}-peptide (A{beta}) fibrils and catalyze the proteolysis of apolipoprotein A-I and A{beta}. Here, recombinant TTR is shown to have proteolytic activity against specific conformations of -synuclein (aSyn), a protein that accumulates in intraneuronal inclusions characteristic of Parkinsons disease (PD). Our discovery stemmed from the observation of a marked decrease in aSyn aggregation in the presence of submicromolar concentrations of TTR. Using integrated biophysical techniques, including advanced microscopy and mass spectrometry, we found that aSyn aggregation is prevented due to the proteolytic cleavage of free aSyn by TTR, in a reaction that is slower for S-glutathionylated TTR and faster for TTR preparations containing vestigial amounts of [~]70 kDa TTR oligomers (oTTR). Interestingly, this proteolysis-trigger effect is not unique to oTTR since it can also be induced by Teflon and glass surfaces independently of which TTR preparation is tested. Our results indicate that a change in aSyn conformation must precede the proteolysis step. The proteolysis of misfolded aSyn emerges as a possible TTR function with implications for the understanding of different neurodegenerative disorders.
02 /Specification & Classification
Click any tag to browse matching papers- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The inhibition of cellular toxicity of amyloid-beta by dissociated transthyretin
Q. Cao, D. H. Anderson, … L. Saelices·bioRxiv·Mar 11, 2020
- A Facile Method to Produce N-Terminally Truncated α-Synuclein
R. J. Thrush, D. M. Vadukul, F. A. Aprile·bioRxiv·Feb 21, 2022
- AUTOTAC-mediated targeted degradation of transthyretin aggregates ameliorates hereditary transthyretin amyloidosis
Hee Yeon Kim, Daniel Youngjae Park, … Yong Tae Kwon·bioRxiv·Feb 24, 2026
- N-terminal acetylation reduces α-synuclein pathology in models of Parkinson's disease
Esther del Cid‐Pellitero, Thomas Goiran, … Edward A. Fon·Neurobiology of DiseasePeer-reviewed·Jun 11, 2026
- Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein
Natalie Landeck, Katherine E. Strathearn, … J. C. Rochet·Molecular NeurodegenerationPeer-reviewed·Sep 8, 2020
- Dissecting the differential role of C-terminal truncations in the regulation of aSyn pathology formation and the biogenesis of Lewy bodies
Anne‐Laure Mahul‐Mellier, Melek Firat Altay, … Hilal Ahmed Lashuel·bioRxiv·Nov 29, 2024